Dr. Omar Alshaer presents a real patient case*:

A case study of HR+, HER2- ABC with metastases beyond the bone, a concerning clinical characteristic1-4

Disease characteristics that typically confer a less favorable prognosis. Visceral and bone metastases were a concerning clinical characteristic in MONARCH 2. Pre-planned subgroup analyses of OS and PFS were performed in the pre- or perimenopausal population.

For more information, see page 5.


Dr. Omar Alshaer, MD, is Head Section of medical oncology on Security Forces Hospital in Riyadh.

*Patient name is kept anonymous to maintain confidentiality


This case study presents a real patient and disease characteristics. The efficacy of abemaciclib in combination with fulvestrant (FUL) is sourced from MONARCH 2, the Verzenio + FUL trial.


This clinical case presentation has been sponsored by Eli Lilly and Company.


Verzenio is indicated for the treatment of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced or metastatic breast cancer (MBC)1:

  In combination with fulvestrant for women with disease progression following endocrine therapy

  In combination with an aromatase inhibitor (AI) for postmenopausal women as initial endocrine-based therapy

  As a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting




Please see Select Important Safety Information throughout, and full Prescribing Information for Verzenio.

Categories: All articles


Leave a Reply

Your email address will not be published. Required fields are marked *